Table 11

Summary of study characteristics for RCTs of antipsychotic drugs in people with first-episode or early schizophrenia.

Olanzapine vs. haloperidolOlanzapine vs. quetiapineOlanzapine vs. risperidoneRisperidone vs. haloperidolRisperidone vs. quetiapine
k (total N)3 (331)1 (267)3 (446)5 (1102)1 (267)
Study IDDEHAAN2003
Jones1998
LIEBERMAN 2003A
MCEVOY2007AJones1998
MCEVOY2007A
VANNIMWEGEN 2008
Emsley1995
Jones1998
LEE2007
MOLLER2008
SCHOOLER2005
MCEVOY2007A
Diagnostic criteriaDSM-IVDSM-IVDSM-IVDSM-III, DSM-IVDSM-IV
Baseline severityPANSS total: ~81 (SD 15) (LIEBERMAN2003A)PANSS total: mean ~74 (SD ~16)PANSS total: mean ~74 (SD 16) (MCEVOY2007A)PANSS total: range 77.3 to 94.2PANSS total: mean ~74 (SD 16)
Selected inclusion criteriaDEHAAN2003: 1–2 psychotic episodes; aged 17–28 years
Jones1998: first 5 years of illness; aged 18–65 years
LIEBERMAN2003A: experienced psychotic symptoms for ≥ 1 month but not more than 60 months; aged 16–40 years
Participants had to be in first-episode of their psychotic illness & had to be continuously ill for ≥1 month & no more than 5 monthsJones1998: first 5 years of illness
MCEVOY2007A: participants had to be in first-episode of their psychotic illness & had to be continuously ill for ≥1 month & no more than 5 months
VANNIMWEGEN 2008: recent onset; aged 18–30 years
Emsley1995: first-episode
Jones1998: first 5 years of illness; aged 18–65 years
LEE2007: drug-naïve
MOLLER2008: first-episode; aged 18–60 years
SCHOOLER2005: schizophrenia <1 year, during which there were no more than two psychiatric hospitalisations for psychosis & ≤12 weeks cumulative exposure to antipsychotics; aged 16–45 years
Participants had to be in first-episode of their psychotic illness & had to be continuously ill for ≥1 month & no more than 5 months
Age of participantsDEHAAN2003: 17–26 years
Jones1998: mean ~29 years
LIEBERMAN 2003A: mean 23.9 (SD 4.6)
16–44 years, mean 24.5 (SD 5.8)Jones1998: mean ~29 years
MCEVOY2007A: 16–44 years, mean 24.5(SD 5.8)
VANNIMWEGEN 2008: mean 25 years
Emsley1995: 15–50 years, median ~23 years
Jones1998: mean ~29 years
LEE2007: mean 32.6 (SD 1) years
MOLLER2008: mean 30.1 (9.8) years
SCHOOLER2005: mean ~24 years
16–44 years, mean 24.5 (SD 5.8) years
SettingInpatient and outpatientInpatient and outpatientInpatient and outpatientInpatient and outpatientInpatient and outpatient
Duration of treatmentShort-term: 6 weeksShort-term: 6 weeksShort-term: 6–8 weeks
Medium-term: 12 weeksMedium-term: 24–30 weeks
Long-term: 54– 104 weeksLong-term: 52 weeksLong-term: 52–54 weeksLong-term: 54– 104 weeksLong-term: 52 weeks
Medication dose (mg/day)Olanzapine: 5– 20 (range)
Haloperidol: 2.5–20 (range)
Olanzapine: 2.5–20 (range)
Quetiapine: 100–800 (range)
Olanzapine: 2.5– 20 (range)
Risperidone: 0.5– 10 (range)
Risperidone: 2– 10 (range)
Haloperidol: 1– 20 (range)
Risperidone: 0.5–4 (range)
Quetiapine: 100–800 (range)

From: 6, Pharmacological interventions in the treatment and management of schizophrenia

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.